Skip to main content
. 2017 Apr 20;10(7):537–544. doi: 10.1177/1756283X17702614

Table 1.

Patient baseline characteristics (n = 18).

EUBD (n = 18)
Sex, male/female, ratio (%) 11/7 (61.1)
Age (years), mean (SD) 68.8 (16.4)
 median (range) 74 (35.4–94.4)
WHO status, mean (SD) 2.1 (0.5)
Cancer primary:
 Pancreatic adenocarcinoma, n (%) 8 (44.4)
 Hilar cholangiocarcinoma, n (%) 5 (27.8)
 Colorectal adenocarcinoma, n (%) 3 (16.7)
 Gastric adenocarcinoma,n (%) 2 (11.1)
Ascites, n (%) 5 (27.8)
Septic cholangitis, n (%) 9 (50)
Total bilirubin, mean (SD), mg/dl 12.2 (7.3)
Hilar obstruction, n (%)
 Local recurrence 6 (33.3)
 Hepatic metastases 4 (22.2)
 Pancreatic mass 3 (16.7)
 Hilar cholangiocarcinoma 3 (16.7)
 Peritoneal carcinomatosis nodule 2 (7.1)
Reasons for failure or preclusion of transpapillary drainage (%)
 Surgically modified anatomy 10 (55.6)
 Impassable stricture at ERCP 7 (38.9)
 Duodenal obstruction 1 (5.6)
Bismuth Classificationa
 I–II 7 (47.7)
 III 7 (47.7)
 IV 1 (6.7)
a

Exclusion of three patients who presented unclassable hilar stenosis (hepatic surgery) in the Bismuth Classification.